FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2911331320> ?p ?o ?g. }

• W2911331320 endingPage "1678" @default.
• W2911331320 startingPage "1669" @default.
• W2911331320 abstract "We aimed to investigate the impact of genetic alterations on the efficacy of poziotinib in a phase II clinical trial of patients with heavily treated HER2-positive metastatic breast cancer (BC). We performed targeted ultra-deep sequencing with a customized cancer gene panel and RNA expression assay using BC specimens. Of 106 patients, biomarker data were available for 85. Copy number (CN) amplifications of HER2 were observed in 72 patients (85%), and CN >8 in 50 (59%). Single nucleotide variants (SNVs) of HER2 were found in 16 patients (19%). Genetic alterations of PIK3CA pathway were found in 40 patients (47%). Median progression free survival (PFS) of the biomarker analysis group was 3.61 months. In terms of PFS, HER2 with CN >8 prolonged (hazard ratio (HR) 0.61, 95% CI: 0.38, 0.97, p = 0.037) and alteration of PIK3CA pathway shortened the duration of survival (HR 2.25, 95% CI: 1.39, 3.63, p = 0.001). SNVs of HER2 increased survival duration, but the effect was not significant (HR: 0.58, 95% CI: 0.31, 1.08, p = 0.085). In addition, SNVs in the ERBB3 cytoplasmic domain decreased poziotinib response (HR: 4.58, 95% CI: 2.02, 10.37, p < 0.001). In multigene analysis, BC with HER2 CN >8 and intact PIK3CA pathway had significantly longer PFS compared to others (HR: 0.37, 95% CI: 0.21, 0.66, p = 0.001), while SNVs in the ERBB3 cytoplasmic domain predicted poor prognosis (HR: 4.28, 95% CI: 1.71, 10.71, p < 0.001). In conclusion, HER2 CN amplification, PIK3CA pathway alteration, and ERBB3 cytoplasmic mutation showed predictive roles on clinical outcomes of HER2-positive MBC treated with poziotinib." @default.
• W2911331320 created "2019-02-21" @default.
• W2911331320 creator A5003283147 @default.
• W2911331320 creator A5003510838 @default.
• W2911331320 creator A5005962138 @default.
• W2911331320 creator A5007089296 @default.
• W2911331320 creator A5012153148 @default.
• W2911331320 creator A5015230939 @default.
• W2911331320 creator A5015532769 @default.
• W2911331320 creator A5017506744 @default.
• W2911331320 creator A5028906808 @default.
• W2911331320 creator A5038366277 @default.
• W2911331320 creator A5049348377 @default.
• W2911331320 creator A5054519943 @default.
• W2911331320 creator A5057060265 @default.
• W2911331320 date "2019-02-27" @default.
• W2911331320 modified "2023-10-16" @default.
• W2911331320 title "Molecular alterations and poziotinib efficacy, a pan‐HER inhibitor, in human epidermal growth factor receptor 2 (HER2)‐positive breast cancers: Combined exploratory biomarker analysis from a phase II clinical trial of poziotinib for refractory HER2‐positive breast cancer patients" @default.
• W2911331320 cites W1964807436 @default.
• W2911331320 cites W1984007340 @default.
• W2911331320 cites W1984068087 @default.
• W2911331320 cites W2020372547 @default.
• W2911331320 cites W2056427943 @default.
• W2911331320 cites W2059411043 @default.
• W2911331320 cites W2080645865 @default.
• W2911331320 cites W2099456677 @default.
• W2911331320 cites W2101979288 @default.
• W2911331320 cites W2104659222 @default.
• W2911331320 cites W2110444464 @default.
• W2911331320 cites W2112621891 @default.
• W2911331320 cites W2114195503 @default.
• W2911331320 cites W2138601221 @default.
• W2911331320 cites W2139135964 @default.
• W2911331320 cites W2145477245 @default.
• W2911331320 cites W2150131459 @default.
• W2911331320 cites W2151101674 @default.
• W2911331320 cites W2154397429 @default.
• W2911331320 cites W2159967578 @default.
• W2911331320 cites W2161422104 @default.
• W2911331320 cites W2166199281 @default.
• W2911331320 cites W2168133698 @default.
• W2911331320 cites W2195827035 @default.
• W2911331320 cites W2318605753 @default.
• W2911331320 cites W2341308894 @default.
• W2911331320 cites W2352525452 @default.
• W2911331320 cites W2461625475 @default.
• W2911331320 cites W2560406314 @default.
• W2911331320 cites W2587365770 @default.
• W2911331320 cites W2589558051 @default.
• W2911331320 cites W2752545514 @default.
• W2911331320 cites W2762097676 @default.
• W2911331320 cites W2766573610 @default.
• W2911331320 cites W2768980003 @default.
• W2911331320 cites W2785610956 @default.
• W2911331320 cites W4247053599 @default.
• W2911331320 doi "https://doi.org/10.1002/ijc.32188" @default.
• W2911331320 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30720867" @default.
• W2911331320 hasPublicationYear "2019" @default.
• W2911331320 type Work @default.
• W2911331320 sameAs 2911331320 @default.
• W2911331320 citedByCount "13" @default.
• W2911331320 countsByYear W29113313202020 @default.
• W2911331320 countsByYear W29113313202021 @default.
• W2911331320 countsByYear W29113313202022 @default.
• W2911331320 countsByYear W29113313202023 @default.
• W2911331320 crossrefType "journal-article" @default.
• W2911331320 hasAuthorship W2911331320A5003283147 @default.
• W2911331320 hasAuthorship W2911331320A5003510838 @default.
• W2911331320 hasAuthorship W2911331320A5005962138 @default.
• W2911331320 hasAuthorship W2911331320A5007089296 @default.
• W2911331320 hasAuthorship W2911331320A5012153148 @default.
• W2911331320 hasAuthorship W2911331320A5015230939 @default.
• W2911331320 hasAuthorship W2911331320A5015532769 @default.
• W2911331320 hasAuthorship W2911331320A5017506744 @default.
• W2911331320 hasAuthorship W2911331320A5028906808 @default.
• W2911331320 hasAuthorship W2911331320A5038366277 @default.
• W2911331320 hasAuthorship W2911331320A5049348377 @default.
• W2911331320 hasAuthorship W2911331320A5054519943 @default.
• W2911331320 hasAuthorship W2911331320A5057060265 @default.
• W2911331320 hasBestOaLocation W29113313201 @default.
• W2911331320 hasConcept C115456853 @default.
• W2911331320 hasConcept C121608353 @default.
• W2911331320 hasConcept C126322002 @default.
• W2911331320 hasConcept C143998085 @default.
• W2911331320 hasConcept C207103383 @default.
• W2911331320 hasConcept C2775930923 @default.
• W2911331320 hasConcept C2777329042 @default.
• W2911331320 hasConcept C2779438470 @default.
• W2911331320 hasConcept C2779786085 @default.
• W2911331320 hasConcept C2781197716 @default.
• W2911331320 hasConcept C44249647 @default.
• W2911331320 hasConcept C530470458 @default.
• W2911331320 hasConcept C54355233 @default.
• W2911331320 hasConcept C71924100 @default.
• W2911331320 hasConcept C86803240 @default.
• W2911331320 hasConceptScore W2911331320C115456853 @default.
• W2911331320 hasConceptScore W2911331320C121608353 @default.
• W2911331320 hasConceptScore W2911331320C126322002 @default.

• next